MASS SPECTROMETRY ENABLES PRECISE MONITORING OF BISPECIFIC ANTIBODY THERAPY IN MULTIPLE MYELOMA

EHA Library, M Teresa Cedena, 4160120

GENOME-WIDE LOSS-OF-FUNCTION CRISPR SCREENS PINPOINT PSME1 AS DETERMINANT FOR CARFILZOMIB RESISTANCE IN MULTIPLE MYELOMA

EHA Library, Maja Jakobsen, 4160121

3D BIOMIMETIC MICROGEL PLATFORM FOR MULTIPLE MYELOMA: REPLICATING TUMOUR MICROENVIRONMENT ON CELL LINES AND PATIENT-DERIVED CELLS.

EHA Library, Maria Inmaculada Garcia-Briega, 4160122

PAEONIFLORIN AMELIORATES BORTEZOMIB-INDUCED PERIPHERAL NEUROPATHY BY RECTIFYING ABNORMAL INTERLEUKIN-6 SECRETION AND AUTOPHAGY LEVEL

EHA Library, Xing Cui, 4160123

DEGRADATION OF IKZF1 VIA E3 UBIQUITIN LIGASE X BY DNA DEMETHYLATING AGENTS IS A POTENTIAL THERAPEUTIC TARGET FOR MULTIPLE MYELOMA

EHA Library, Yuta Yamamoto, 4160124

SYSTEMIC DISSEMINATION AND RESPONSIVENESS TO CLINICALLY-USED THERAPEUTICS IS RECAPITULATED IN A CHICK EMBRYO XENOGRAFT MODEL OF MULTIPLE MYELOMA

EHA Library, Izabela Cymer, 4160125

PHASE 1, FIRST-IN-HUMAN STUDY OF ISB 2001: A BCMAXCD38XCD3-TARGETING TRISPECIFIC ANTIBODY FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)—DOSE ESCALATION (DE) RESULTS.

EHA Library, Hang Quach, 4160126

CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (KRD) VERSUS ELOTUZUMAB-KRD IN TRANSPLANT-ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: INITIAL RESULTS FOR 3-YEAR PROGRESSION-FREE SURVIVAL (PFS)

EHA Library, Stefan Knop, 4160127

UPDATED INTERIM RESULTS OF SONROTOCLAX + DEXAMETHASONE IN PATIENTS WITH T(11;14)-POSITIVE RELAPSED/REFRACTORY MULTIPLE MYELOMA: AN ALL-ORAL TREATMENT

EHA Library, Binod Dhakal, 4160128

LONG TERM EFFICACY AND SAFETY OF ETENTAMIG (ABBV-383), A B-CELL MATURATION ANTIGEN (BCMA) BISPECIFIC ANTIBODY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Muhamed Baljević, 4160129

MEZIGDOMIDE (MEZI) PLUS DEXAMETHASONE (DEX) AND BORTEZOMIB (BORT) OR CARFILZOMIB (CFZ) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED RESULTS FROM THE CC-92480-MM-002 TRIAL

EHA Library, Irwindeep Sandhu, 4160130

OUTCOME OF EARLY INTERVENTION AT MRD PROGRESSION IN MULTIPLE MYELOMA PATIENTS FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION: : A RETROSPECTIVE ANALYSIS

EHA Library, Juan Li, 4160131

BIRTAMIMAB SAFETY IN AL AMYLOIDOSIS PATIENT SUBGROUPS: MAYO STAGE I-III VS STAGE IV AND PREVIOUSLY TREATED PATIENTS RECEIVING MONOTHERAPY VS NEWLY DIAGNOSED PATIENTS WITH CONCOMITANT STANDARD OF CARE

EHA Library, Ashutosh Wechalekar, 4160132

DREAMM-8: MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH BELANTAMAB MAFODOTIN, POMALIDOMIDE, AND DEXAMETHASONE VS STANDARD-OF-CARE REGIMEN

EHA Library, Meletios Dimopoulos, 4160133

ISA-VRD IMPROVES OUTCOMES IN HIGH-RISK (HR) NEWLY DIAGNOSED TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA (NDMM TI) USING THE IMS/IMWG CONSENSUS HR DEFINITION: RESULTS FROM THE BENEFIT PHASE 3 TRIAL (IFM 2020-05)

EHA Library, Jill Corre, 4160134

UPDATED RESULTS FROM PHASE 3 DREAMM-8 STUDY OF BELANTAMAB MAFODOTIN PLUS POMALIDOMIDE AND DEXAMETHASONE VS POMALIDOMIDE PLUS BORTEZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Meletios Dimopoulos, 4160135

ISATUXIMAB, BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (ISA-VRD) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): OUTCOMES IN PATIENTS WITH 1Q21+ STATUS IN THE PHASE 3 IMROZ STUDY

EHA Library, Meletios Dimopoulos, 4160136

CHALLENGING THE CONCEPT OF FUNCTIONAL HIGH-RISK MYELOMA THROUGH ADVANCED TRANSCRIPTIONAL AND GENETIC PROFILING.

EHA Library, Sina A Beer, 4160137

DARATUMUMAB, BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE (DVRD) VS VRD IN TRANSPLANT-INELIGIBLE/TRANSPLANT-DEFERRED NEWLY DIAGNOSED MULTIPLE MYELOMA: PHASE 3 CEPHEUS TRIAL CYTOGENETIC SUBGROUP ANALYSIS

EHA Library, Nizar J Bahlis, 4160138

PROSPECTIVE FUNCTIONAL BONE DISEASE EVALUATION OF NEWLY DIAGNOSED MULTIPLE MYELOMA WITH COMBINED USE OF (18)F-FDG-PET/CT AND WHOLE-BODY DIFFUSION WEIGHTED MAGNETIC RESONANCE

EHA Library, Marco Talarico, 4160139

EXTENDED DOSING SCHEDULE OF BELANTAMAB MAFODOTIN IN COMBINATION WITH DARATUMUMAB, LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: THE PHASE 1/2 BELADRD STUDY

EHA Library, Evangelos Terpos, 4160140

A MULTICENTER PHASE 2 STUDY DESIGNED TO OPTIMIZED THE SCHEDULE OF BELANTAMAB MAFODOTIN PLUS BORTEZOMIB AND DEXAMETHASONE IN RELAPSED REFRACTORY MULTIPLE MYELOMA

EHA Library, Tereza Popková, 4160141

CYTOPENIAS AND INFECTIONS FOLLOWING CILTACABTAGENE AUTOLEUCEL IN HEAVILY-PRETREATED RELAPSED OR REFRACTORY MULTIPLE MYELOMA

EHA Library, Danai Dima, 4160142

OUTCOMES OF MYELOMA PATIENTS WITH DEL 17P WHO UNDERWENT AUTOLOGOUS STEM CELL TRANSPLANTATION IN EBMT CENTRES BETWEEN 2016 AND 2022

EHA Library, Patrick Hayden, 4160143

IBERDOMIDE, BORTEZOMIB, AND DEXAMETHASONE (IBERVD) IN TRANSPLANT-INELIGIBLE (TNE) NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): UPDATED RESULTS FROM THE CC-220-MM-001 TRIAL

EHA Library, Darrell White, 4160144

SERUM FREE LIGHT CHAIN DIFFERENCE (DSFLC) AS A ROBUST PREDICTOR FOR MULTIPARAMETER FLOW CYTOMETRY-BASED MINIMAL RESIDUAL DISEASE POSITIVITY IN MULTIPLE MYELOMA: A COHORT STUDY GUIDING OPTIMAL MONITORING STRATEGIES

EHA Library, Fan Zhang, 4160145

DREAMM-7 STUDY OF BELANTAMAB MAFODOTIN + BORTEZOMIB + DEXAMETHASONE VS DARATUMUMAB + BORTEZOMIB + DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A HIGH-RISK CYTOGENETIC SUBGROUP ANALYSIS

EHA Library, María-Victoria Mateos, 4160146

DREAMM-8 STUDY OF BELANTAMAB MAFODOTIN + POMALIDOMIDE + DEXAMETHASONE VS POMALIDOMIDE + BORTEZOMIB + DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A HIGH-RISK CYTOGENETIC SUBGROUP ANALYSIS

EHA Library, Meletios Dimopoulos, 4160148

FIRST RESULTS FROM REALITAL: A EUROPEAN MULTI-COUNTRY OBSERVATIONAL RETROSPECTIVE STUDY OF TALQUETAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA OUTSIDE OF CLINICAL TRIALS

EHA Library, K. Martin Kortüm, 4160149

IMPACT OF SELINEXOR DOSE REDUCTIONS ON SELINEXOR, BORTEZOMIB, DEXAMETHASONE (SVD) OUTCOMES IN PATIENTS (PTS) WITH LENALIDOMIDE (LEN)-REFRACTORY MULTIPLE MYELOMA (MM): BOSTON TRIAL SUBGROUP ANALYSIS

EHA Library, Sosana Delimpasi, 4160150

TO TREAT OR NOT? A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED STUDIES ON SMOLDERING MULTIPLE MYELOMA

EHA Library, Ioannis Ntanasis-Stathopoulos, 4160151

HIGHER USE OF HDT/ASCT IN FIRST-LINE LEADS TO SUPERIOR SURVIVAL IN MULTIPLE MYELOMA PATIENTS AGED 66-70: REAL-WORLD EVIDENCE FROM THE NETHERLANDS

EHA Library, Koen Klomberg, 4160152

RISK FACTORS AND MODES OF PROGRESSION IN SOLITARY BONE PLASMACYTOMA WITH OR WITHOUT MINIMAL MARROW INVOLVEMENT

EHA Library, Kenneth Jin Chang Lim, 4160153

TALQUETAMAB IMMUNOGENICITY AND IMPACT ON EXPOSURE, EFFICACY, AND SAFETY: ANALYSES FROM PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN MONUMENTAL-1

EHA Library, Indrajeet Singh, 4160154

RESUMPTION OF BONE-MODIFYING AGENTS IN RELAPSED MULTIPLE MYELOMA AND PATIENT OUTCOMES: A REAL-WORLD ANALYSIS

EHA Library, Malcolm Su, 4160155

THE ANTI-BCMA ANTIBODY-DRUG CONJUGATE HDP-101 WITH A NOVEL AMANITIN PAYLOAD SHOWS PROMISING DATA IN RELAPSED/ REFRACTORY MULTIPLE MYELOMA IN A PHASE 1/2A CLINICAL TRIAL AS IT ADVANCES INTO COHORT 7.

EHA Library, Shambavi Richard, 4160156

ISATUXIMAB, BORTEZOMIB, LENALIDOMIDE, DEXAMETHASONE (ISA-VRD) IN PATIENTS WITH TRANSPLANT-INELIGIBLE (TI) NEWLY DIAGNOSED MYELOMA (NDMM) AND PLASMACYTOMAS: IMROZ SUBGROUP ANALYSIS

EHA Library, Elena Zamagni, 4160157

SAFETY AND EFFICACY OF IXAZOMIB, POMALIDOMIDE AND DEXAMETHASONE AS 2ND OR 3RD LINE TREATMENT FOR TRIPLE EXPOSED MULTIPLE MYELOMA PATIENTS: A PHASE II MULTI-CENTER TRIAL (IPOD-790)

EHA Library, Tamir Shragai, 4160158

ISATUXIMAB IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA WHO RELAPSED AFTER ONE LINE OF LENALIDOMIDE-CONTAINING THERAPY: A PHASE 2 STUDY BY THE GREEK MYELOMA STUDY GROUP

EHA Library, Evangelos Terpos, 4160159

ETOPOSIDE+CYTARABINE+PEGFILGRASTIM VS CYCLOPHOSPHAMIDE+GRANULOCYTE COLONY-STIMULATING FACTOR FOR STEM-CELL MOBILIZATION IN PATIENTS WITH MULTIPLE MYELOMA: A PHASE III TRIAL

EHA Library, Peipei Ye, 4160160

INTERIM ANALYSIS OF MRD-GUIDED MAINTENANCE THERAPY WITH BELANTAMAB MAFODOTIN AND LENALIDOMIDE AFTER AUTO-HCT IN NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Yosra Aljawai, 4160161

DEVELOPMENT AND VALIDATION OF A MULTIPLE MYELOMA-SPECIFIC COMORBIDITY INDEX FROM A KOREAN NATIONWIDE COHORT: CAREMM-2108

EHA Library, Sung-Soo Park, 4160162

WHOLE BODY MAGNETIC RESONANCE IMAGING FOR EARLY TREATMENT RESPONSE EVALUATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Ioannis Ntanasis-Stathopoulos, 4160163

HIGH PREVALENCE AND INCIDENCE OF ATRIAL FIBRILLATION AMONG PATIENTS WITH MULTIPLE MYELOMA. A POPULATION-BASED STUDY ON 8 672 PATIENTS DIAGNOSED 2008-2021 FROM THE SWEDISH MYELOMA REGISTRY.

EHA Library, Karin Larsson, 4160164

SEQUENTIAL BCMA CAR T-CELL THERAPY IN REFRACTORY MULTIPLE MYELOMA

EHA Library, Tim Richardson, 4160165

BASELINE OCULAR CONDITIONS AND INCIDENCE OF OCULAR EVENTS IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) FROM THE DREAMM-7 AND DREAMM-8 TRIALS OF BELANTAMAB MAFODOTIN (BELAMAF)

EHA Library, Dimopoulos Meletios, 4160166

REAL-WORLD TREATMENT PATTERNS AND CLINICAL OUTCOMES OF RELAPSED/REFRACTORY MULTIPLE MYELOMA IN ASIA - AN ASIAN MYELOMA NETWORK STUDY

EHA Library, Cinnie Soekojo, 4160167

DENOSUMAB IN MULTIPLE MYELOMA: LONGITUDINAL IMPACT ON BONE MINERAL DENSITY DYNAMICS AND PROGRESSION-FREE SURVIVAL — A MULTICENTER PROSPECTIVE COHORT ANALYSIS

EHA Library, Li Bao, 4160168

EXPOSURE-RESPONSE ANALYSES OF VARIOUS EFFICACY AND SAFETY ENDPOINTS IN SUPPORT OF REGISTRATIONAL DOSE SELECTION OF LINVOSELTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Swathi Namburi, 4160169

A RETROSPECTIVE STUDY OF ISATUXIMAB-POMALIDOMIDE-DEXAMETHASONE IN RELAPSED/REFRACTORY SYSTEMIC AL AMYLOIDOSIS

EHA Library, Sargam Vohra, 4160170

EFFICACY AND SAFETY OF ETENTAMIG, A BCMA X CD3 BISPECIFIC ANTIBODY, IN BLACK PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A POOLED ANALYSIS OF PHASE 1 TRIALS

EHA Library, Eben Lichtman, 4160171

SURVIVAL BENEFIT OF CILTACABTAGENE AUTOLEUCEL IN SECOND-LINE COMPARED WITH LATER-LINE TREATMENT OF LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA: UPDATED TREATMENT POSITIONING MODEL ANALYSIS

EHA Library, Roberto Mina, 4160172

COMPREHENSIVE ANALYSIS OF SOLUBLE BCMA AS A TUMOR MARKER FOR MONITORING OF TUMOR BURDEN IN PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Masanori Toho, 4160173

QUADRUPLET DARATUMUMAB IN COMBINATION WITH BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE AS FRONT-LINE REGIMEN IMPROVED CLINICAL OUTCOMES IN HIGH-RISK MYELOMA PATIENTS IN CHINA: A MULTI-CENTERED PROSPECTIVE REAL-WORLD STUDY.

EHA Library, Junling Zhuang, 4160174

CLINICAL OUTCOMES OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WITH AND WITHOUT EXTRAMEDULLARY DISEASE

EHA Library, Peter Voorhees, 4160175

CLINICAL CHARACTERISTICS AND OUTCOMES OF UNTREATED AL-AMYLOIDOSIS PATIENTS: AN ANALYSIS OF A POPULATION-BASED REGISTRY

EHA Library, Flores Weverling, 4160176

REALITEC SUBGROUP ANALYSIS: A MULTI-COUNTRY OBSERVATIONAL RETROSPECTIVE STUDY OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA OUTSIDE OF CLINICAL TRIALS

EHA Library, Rakesh Popat, 4160177

EFFICACY AND SAFETY OF LESS FREQUENT DOSING WITH ELRANATAMAB (ELRA) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): A US SUBGROUP ANALYSIS FROM MAGNETISMM-3

EHA Library, Noopur Raje, 4160178

RETROSPECTIVE STUDY TO DESCRIBE THE CLINICAL CHARACTERISTICS, MANAGEMENT, AND OUTCOMES OF TALQUETAMAB IN PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA TREATED OUTSIDE CLINICAL TRIALS IN SPAIN.

EHA Library, Maria Jesus Blanchard Rodriguez, 4160179

INVESTIGATION INTO SECONDARY EXTRAMEDULLARY MYELOMA: A NOVEL FIVE-PREDICTOR SCORING SYSTEM HIGHLIGHTING DOUBLE-HIT CYTOGENETICS

EHA Library, Yi Tao, 4160180

TREATMENT PATTERNS AND EFFECTIVENESS IN AN ANTI-CD38 AND LENALIDOMIDE PRETREATED RRMM POPULATION: DATA FROM TWO REAL-WORLD DATASETS

EHA Library, Meera Mohan, 4160181

REAL-WORLD CLINICAL PRACTICE IN ITALIAN PATIENTS WITH MULTIPLE MYELOMA: PRELIMINARY ANALYSIS OF THE MY MYELOMA MULTICENTER REGISTRY

EHA Library, Giuseppe Bertuglia, 4160182

INDIRECT COMPARISON OF LINVOSELTAMAB VERSUS ELRANATAMAB FOR TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Sundar Jagannath, 4160183

DE-ESCALATED TECLISTAMAB DOSING IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: CZECH MYELOMA GROUP REAL-WORLD EVIDENCE STUDY

EHA Library, Martin Stork, 4160184

IMWG/ECOG FRAILTY ASSESSMENT IN NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS

EHA Library, Chengcheng Fu, 4160185

EARLY CLINICAL AND NON-GENETIC PREDICTORS OF FUNCTIONAL HIGH RISK NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS

EHA Library, Massimo Offidani, 4160186

EUROPEAN CLINICAL VIEWS ON THE CHALLENGES OF TREATING PATIENTS WITH AUTOLOGOUS CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY AND BISPECIFIC ANTIBODIES IN MULTIPLE MYELOMA

EHA Library, Molly Purser, 4160187

STEM CELL TRANSPLANTATION IN FIT ELDERLY MULTIPLE MYELOMA PATIENTS IS SAFE AND EFFECTIVE, A REAL-WORLD AGE GROUP COMPARISON

EHA Library, Koen Klomberg, 4160188

IMPACT OF FREE LIGHT CHAINS BURDEN ON AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) OUTCOMES FOR AL AMYLOIDOSIS

EHA Library, Samer Srour, 4160189

BELANTAMAB FOR THE TREATMENT OF MULTIPLE MYELOMA: RESULTS FROM PART 1 OF THE FIRST-IN-HUMAN PHASE 1/2 DREAMM-20 TRIAL

EHA Library, Hang Quach, 4160190

MAGNETISMM-30: A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH IBERDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Alexander Lesokhin, 4160191

Identification of BARD1 mutation as a novel indicator for constructing a prognostic nomogram in multiple myeloma

EHA Library, Lin Ling, 4160192

RISK-SCORING MODEL FOR THE PROGNOSTIC IMPACT OF ADDITIONAL COPIES OF CHROMOSOME 1Q IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Yi Li, 4160193

REAL-WORLD EFFECTIVENESS OF BELANTAMAB MAFODOTIN, BCMA-CD3 BISPECIFIC ANTIBODIES AND TALQUETAMAB IN PATIENTS WITH TRIPLE-CLASS-EXPOSED MULTIPLE MYELOMA. FIRST RESULTS FROM THE DANISH ABCD-STUDY.

EHA Library, Astrid Hundebøll Torpe, 4160194

THE EFFECT OF SWITCHING TO LESS FREQUENT DOSING ON PATIENT-REPORTED OUTCOMES AMONG PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH ELRANATAMAB

EHA Library, Nizar J Bahlis, 4160195

PREDICTING MOBILIZATION OUTCOMES IN MULTIPLE MYELOMA PATIENTS USING A NOMOGRAM: A RETROSPECTIVE STUDY

EHA Library, Juan Li, 4160196

REAL-WORLD CHARACTERISTICS AND SAFETY AND EFFECTIVENESS OF TALQUETAMAB AMONG PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): AN ELECTRONIC MEDICAL RECORD AND CHART REVIEW STUDY

EHA Library, Cesar Rodriguez, 4160197

THE TREATMENT OF PATIENTS PROGRESSING AFTER LENALIDOMIDE MAINTENANCE: AN ITALIAN REAL-LIFE STUDY OF 284 CASES

EHA Library, Gregorio Barilà, 4160198

PREDICTING CARDIAC AND RENAL RESPONSE IN LIGHT CHAIN (AL) AMYLOIDOSIS USING AN ENSEMBLE MACHINE LEARNING MODEL

EHA Library, Louis Williams, 4160199

TOXICITY-RELATED TREATMENT CESSATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA - RISK FACTORS AND SURVIVAL: AN ANALYSIS FROM THE APAC AND ANZ MYELOMA AND RELATED DISEASES REGISTRY

EHA Library, Ji Hyun Lee, 4160200

EVALUATING THE IMPACT OF ETHNICITY ON THE OUTCOME OF MULTIPLE MYELOMA IN AUSTRALIA AND NEW ZEALAND: DATA FROM THE MYELOMA AND RELATED DISEASES REGISTRY

EHA Library, Silvia Ling, 4160201

RELAPSE FROM MEASURABLE DISEASE NEGATIVITY AS INDICATION FOR TREATMENT IN MULTIPLE MYELOMA: THE PHASE 3 REMNANT STUDY

EHA Library, Frida Bugge Askeland, 4160202

SINGLE AGENT ELRANATAMAB FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (R/R MM) - MULTI-CENTRE REAL-WORLD OUTCOMES FROM 5 UNITED KINGDOM (UK) SITES

EHA Library, Oliver Tomkins, 4160203

BURDEN OF ILLNESS IN PATIENTS WITH MULTIPLE MYELOMA (MM) WHO BECOME TRIPLE CLASS EXPOSED IN THE UK: RESULTS OF A RETROSPECTIVE ANALYSIS FROM THE RETINUE STUDY

EHA Library, Christopher Parrish, 4160204

ALTITUDE-1: REAL-WORLD TREATMENT PATTERNS ASSOCIATED WITH ELRANATAMAB AMONG PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Rahul Banerjee, 4160205

FUNCTIONAL GERIATRIC ASSESSMENT TESTS PREDICT TOXICITY RATES IN FUNCTIONAL HIGH RISK MYELOMA PATIENTS TREATED WITH DARATUMUMAB, CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN A PROSPECTIVE CLINICAL TRIAL

EHA Library, Yael Cohen, 4160206

TRIAL IN PROGRESS: QUINTESSENTIAL - A PHASE 2 STUDY OF ARLOCABTAGENE AUTOLEUCEL (ARLO-CEL) IN TRIPLE- AND QUAD-CLASS EXPOSED PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Krina Patel, 4160207

BROMODOMAIN AND EXTRA-TERMINAL (BET) PROTEIN INHIBITOR, INCB057643, IMPROVES BONE MARROW FUNCTION AND SHIFTS MEGAKARYOPOIESIS TO ERYTHROPOIESIS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS (MPNS)

EHA Library, Diana Alvarez Arias, 4160208

MODELING ADVANCED SYSTEMIC MASTOCYTOSIS: A NOVEL TRANSGENIC MOUSE LINE RECAPITULATES HUMAN DISEASE AND VALIDATES EFFICACY OF AVAPRITINIB

EHA Library, Martina Konantz, 4160209

BCL-XL INHIBITION POTENTIATES INTERFERON-INDUCED APOPTOSIS IN MPN STEM CELLS

EHA Library, Steven Lane, 4160210

INTERNATIONAL MULTICENTRE EVALUATION OF ARTIFICIAL INTELLIGENCE (AI) AUGMENTED FIBROSIS GRADING IN A REAL-WORLD, CLINICAL COHORT OF 1000 PATIENTS

EHA Library, Timothy Ebsworth, 4160211

3D MODELING OF BONE MARROW FIBROSIS AND ALTERED MEGAKARYOPOIESIS IN MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Christian Di Buduo, 4160212

DECIPHERING FIBROTIC NICHES IN MPN USING NICHESPHERE: A CELLULAR INTERACTION MAP OF BONE MARROW FIBROSIS

EHA Library, Hélène Gleitz, 4160213

CLONAL EVOLUTION DURING MPN TRANSFORMATION IS SHAPED BY A COMPLEX INTERPLAY BETWEEN MUTATION ACQUISITION, GENETIC INTERACTIONS, AND ALLELIC DOSAGE EVENTS

EHA Library, Noushin Farnoud, 4160214

THE DYNAMIC LANDSCAPE OF IMMUNE ENVIRONMENT FOR MM PATIENTS RECEIVING T CELL REDIRECTING THERAPIES

EHA Library, Jin Lu, 4160215

A NOVEL JAK2 INHIBITOR OB756 INHIBITS MEGAKARYOPOIESIS DIFFERENTIATION AND PROPLATELET BIOGENESIS VIA PI3K-AKT SIGNALING PATHWAY IN PATIENTS WITH PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Jian Huang, 4160216

DECIPHERING THE ENHANCER LANDSCAPE OF PTPN11-MUTANT JUVENILE MYELOMONOCYTIC LEUKEMIA

EHA Library, Noel Gómez-Molina, 4160217

CLONAL DYNAMICS AND COMPLEXITY OF HEMATOPOIETIC STEM CELLS CO-MUTATED IN CALR AND TP53 DURING THE TRANSFORMATION OF CLASSICAL MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Syrine Bel Haj Yahia, 4160218

MACROPHAGE POLARIZATION AND PHAGOCYTIC ACTIVITY IN PTPN11-MUTATED JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML): IMPLICATIONS FOR IMMUNE EVASION AND THERAPEUTIC TARGETING

EHA Library, Jun Wang, 4160219

DIETARY IRON AFFECTS HAEMATOLOGY AND BONE HEALTH IN A MOUSE MODEL OF POLYCYTHAEMIA VERA

EHA Library, Cavan Bennett, 4160220